Active immunization with IL‐1 displayed on virus‐like particles protects from autoimmune arthritis

IL‐1 is an important mediator of inflammation and a major cause of tissue damage in rheumatoid arthritis (RA). Therapeutic administration of recombinant IL‐1 receptor antagonist (IL‐1Ra) is efficacious in reducing clinical symptoms of disease, but suffers from several drawbacks, including the need for frequent administrations of large amounts. Here, we show that immunization of mice with either IL‐1α or IL‐1β chemically cross‐linked to virus‐like particles (VLP) of the bacteriophage Qβ elicited a rapid and long‐lasting autoantibody response. The induced Ab efficiently neutralized the binding of the respective IL‐1 molecules to their receptors in vitro and their pro‐inflammatory activities in vivo. In the collagen‐induced arthritis model, both vaccines strongly protected mice from inflammation and degradation of bone and cartilage. Moreover, immunization with either vaccine showed superior efficacy than daily administrations of high amounts of IL‐1Ra. In the T and B cell‐independent collagen Ab transfer model, immunization with the IL‐1β vaccine strongly protected from arthritis, whereas immunization with the IL‐1α vaccine had no effect. Our results suggest that active immunization with IL‐1α, and especially IL‐1β conjugated to Qβ VLP, might become an efficacious and cost‐effective new treatment option for RA and other systemic IL‐1‐dependent inflammatory disorders.

[1]  T. Kündig,et al.  A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-α Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis , 2007, The Journal of Immunology.

[2]  H. Volk,et al.  A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity , 2007, Journal of hypertension.

[3]  G. Jennings,et al.  Vaccination against IL‐17 suppresses autoimmune arthritis and encephalomyelitis , 2006, European journal of immunology.

[4]  J. Thurman,et al.  Alternative Complement Pathway Activation Is Essential for Inflammation and Joint Destruction in the Passive Transfer Model of Collagen-Induced Arthritis1 , 2006, The Journal of Immunology.

[5]  Kutty Selva Nandakumar,et al.  Arthritis induced with cartilage‐specific antibodiesis IL‐4‐dependent , 2006, European journal of immunology.

[6]  G. Burmester,et al.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[7]  K. Schwarz,et al.  Protection against Osteoporosis by Active Immunization with TRANCE/RANKL Displayed on Virus-Like Particles , 2005, The Journal of Immunology.

[8]  Kutty Selva Nandakumar,et al.  Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. , 2005, Journal of immunological methods.

[9]  M. Lathrop,et al.  Variation in IL-1beta gene expression is a major determinant of genetic differences in arthritis aggressivity in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Zagury,et al.  Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. , 2005, Vaccine.

[11]  M. Broder,et al.  Granulomatous infections due to tumor necrosis factor blockade: correction. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Kutty Selva Nandakumar,et al.  Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells , 2004, Arthritis research & therapy.

[13]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Kutty Selva Nandakumar,et al.  Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes. , 2003, The American journal of pathology.

[15]  J. Dayer.  The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. , 2003, Rheumatology.

[16]  G. Burmester,et al.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.

[17]  M. Braun,et al.  Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. , 2003, Arthritis and rheumatism.

[18]  G. Lipowsky,et al.  Regulation of IgG antibody responses by epitope density and CD21‐mediated costimulation , 2002, European journal of immunology.

[19]  M. Braun,et al.  Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. , 2002, Arthritis and rheumatism.

[20]  S. Abramson,et al.  Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. , 2002, Rheumatology.

[21]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[22]  T. Kagari,et al.  The Importance of IL-1β and TNF-α, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis , 2002, The Journal of Immunology.

[23]  C. Benoist,et al.  Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis , 2002, The Journal of experimental medicine.

[24]  K. Bendtzen,et al.  Autoantibodies against interleukin 1α in rheumatoid arthritis: association with long term radiographic outcome , 2002, Annals of the rheumatic diseases.

[25]  D. Hirsh,et al.  The Epistatic Interrelationships of IL-1, IL-1 Receptor Antagonist, and the Type I IL-1 Receptor1 , 2002, The Journal of Immunology.

[26]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[27]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[28]  T. van der Poll,et al.  Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. , 2000, The Journal of infectious diseases.

[29]  Y. Iwakura,et al.  Protective Role of Interleukin-1 in Mycobacterial Infection in IL-1 α/β Double-Knockout Mice , 2000, Laboratory Investigation.

[30]  I. Otterness,et al.  Cytokine vaccination: neutralising IL-1α autoantibodies induced by immunisation with homologous IL-1α , 2000 .

[31]  E. Hirsch,et al.  Effects of Interleukin-1 Receptor Antagonist Overexpression on Infection by Listeria monocytogenes , 1999, Infection and Immunity.

[32]  K. McIntyre,et al.  Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. , 1997, Journal of immunology.

[33]  S. Paul,et al.  Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[35]  T. Pincus,et al.  Prognostic markers of activity and damage in rheumatoid arthritis: why clinical trials and inception cohort studies indicate more favourable outcomes than studies of patients with established disease. , 1995, British journal of rheumatology.

[36]  J. Banchereau,et al.  Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. , 1995, Journal of immunology.

[37]  G. Firestein,et al.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[38]  M. Denis,et al.  Interleukin-1 is involved in mouse resistance to Mycobacterium avium , 1994, Infection and immunity.

[39]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[40]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[41]  K. Bendtzen,et al.  IgG Autoantibodies against Interleukin 1α in Sera of Normal Individuals , 1989 .

[42]  C. Avnstorp,et al.  Interleukin‐1 , 1987 .

[43]  K. Nishioka,et al.  Efficacy of daily compared to intermittent administration of IL-1Ra for protection against bone and cartilage destruction in collagen-challenged mice. , 2003, Clinical and experimental rheumatology.

[44]  T. Kagari,et al.  The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. , 2002, Journal of immunology.

[45]  I. Otterness,et al.  Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. , 2000, Journal of immunological methods.

[46]  Y. Iwakura,et al.  Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. , 2000, Laboratory investigation; a journal of technical methods and pathology.

[47]  T. Pincus.  Long-term outcomes in rheumatoid arthritis. , 1995, British journal of rheumatology.

[48]  K. Bendtzen,et al.  IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. , 1989, Scandinavian journal of immunology.